Search company, investor...

Lamassu Pharma

lamassupharma.com

Founded Year

2018

Stage

Unattributed | Alive

Total Raised

$2.67M

Last Raised

$2.67M | 3 yrs ago

About Lamassu Pharma

Lamassu Pharma develops pharmaceuticals for acute pancreatitis.

Headquarters Location

2530 Meridian Pkwy Suite 300

Durham, North Carolina, 27713,

United States

919-667-8571

Missing: Lamassu Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lamassu Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lamassu Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lamassu Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Lamassu Pharma News

Drug Acceleration Experts Launch New Biotech Startup With Eye On Cancer Treatments, Global Partnerships For Patients

Mar 24, 2022

Physician-scientists who slashed drug development timeline in 2021 now focused on building global partnerships to solve unmet needs for difficult-to-treat diseases Durham, NC /PRNewswire/ - The team of entrepreneur physician-scientists who first developed the novel therapeutic RABI-767 for the treatment of severe acute pancreatitis have launched a new biotech startup to accelerate the development of novel therapeutics for major unmet needs and difficult-to-treat diseases. The startup, Lamassu Bio, Inc., will first focus its research efforts on the development of novel therapeutics for the treatment of multiple cancers, including pancreatic cancer. "Every day there are diseases with unmet needs, like pancreatic cancer, that cause the deaths of thousands of patients," said Dr. Gabi Hanna, MD, Founder and CEO of Lamassu Bio. "The traditional drug approval timeline in the United States, and elsewhere throughout the world, takes so long that most patients with these severe diseases will not live long enough to benefit from drugs currently in development. Our goal is to serve these unmet needs by helping accelerate the time it takes drugs for unmet needs to work through the pipeline—via a combination of innovative science and entrepreneurship centered on patient benefits—and into the hands of patients, where they do the most good." In addition to working towards the acceleration of drug development timelines in the United States, Lamassu Bio will also partner with organizations around the world to bring novel therapeutics for difficult-to-treat diseases to patients in other countries more quickly. These new partnerships will allow scientists to utilize global research knowledge and expertise to accelerate the development and commercialization of therapeutics. "We believe our methods, which have already proven successful in the United States, can benefit patients worldwide. As a result, we're building partnerships with global reach to help establish knowledge bridges that accelerate the development and availability of drugs for unmet needs wherever they exist," said Hanna. "Cancers and other serious diseases don't only confine themselves to the country where a drug is being developed, so we're thinking beyond borders with this new venture, and broadly sharing information so we can find solutions more quickly." In 2018, Hanna, along with Drs. Rabi Hanna, MD and Greg Palmer, PhD, founded Lamassu Pharma, LLC, a biotech startup, in partnership with the Mayo Clinic. Lamassu Pharma is focused on accelerating the drug development timeline by improving processes and communication at every level of development, from initial discovery to safety, IND-enabling, and clinical trials, and finally, through to market. In 2021, Lamassu Pharma announced the successful completion of preclinical toxicology for RABI-767, a novel therapeutic for the treatment of severe acute pancreatitis first discovered at the Mayo Clinic. The successful acceleration of RABI-767 through preclinical trials gave the Lamassu team the proof they needed to take the next step: building a company that could handle multiple projects and partners at one time. "Lamassu Pharma was our first private venture to take our vision out of academia, and it was built conservatively, with one asset in mind: RABI-767," said Hanna. "We were blessed with good investors and partners who believed in our vision and our capability, and a wonderful partner in the Mayo Clinic. All the pieces came together in the right way at the right time, and we were able to get RABI-767 from the discovery research lab to clinical trial-ready in less than 1.5 years. That was unheard of until now. The birth of Lamassu Bio will give us the opportunity to repeat this success many times over both within and outside of the United States, exponentially increasing the number of patients we can help." About Lamassu Bio, Inc. Founded by Drs. Gabi Hanna, Rabi Hanna, and Greg Palmer after of the success of Lamassu Pharma, Lamassu Bio, Inc. aims to take the development of drugs targeting major unmet needs in the field of oncology to the next level. Research efforts at Lamassu Bio focus first on the development of novel therapeutics for the treatment of multiple cancers. Lamassu's team of academicians-turned-biopharmaceutical disruptors is accelerating the drug pipeline in the United States and opening borders to partnerships with researchers around the world to bring treatments to those who need them most. Source: Lamassu Bio, Inc.

Lamassu Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lamassu Pharma Rank

Lamassu Pharma Frequently Asked Questions (FAQ)

  • When was Lamassu Pharma founded?

    Lamassu Pharma was founded in 2018.

  • Where is Lamassu Pharma's headquarters?

    Lamassu Pharma's headquarters is located at 2530 Meridian Pkwy, Durham.

  • What is Lamassu Pharma's latest funding round?

    Lamassu Pharma's latest funding round is Unattributed.

  • How much did Lamassu Pharma raise?

    Lamassu Pharma raised a total of $2.67M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.